Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study

Netakimab is a humanized anti-interleukin-17А monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis. Herein, we report the accumulated efficacy data and safety findings of 54-week netakimab treatment during the PATERA study.

The aim of the study was to assess the long-term efficacy and safety of netakimab in patients with active psoriatic arthritis.

Materials and methods. 194 patients with active psoriatic arthritis despite the previous therapy with nonsteroidal anti-inflammatory drugs, conventional or biologic disease-modifying antirheumatic drugs were initially randomized to receive 120 mg netakimab or placebo (1:1) at weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, 22. At week 16 inadequate responders in placebo group were reassigned to netakimab in a blinded manner. From week 24 all patients receive open-label netakimab. The analyzed period includes 54 weeks.

Results. Netakimab demonstrated sustained treatment response. 94.9% of patients in the netakimab group achieved ACR20 at week 54; 89.5% achieved PASI75 response. Axial disease, dactylitis, and enthesitis significantly improved with netakimab. A similar pattern was observed for placebo/netakimab treated patients. Netakimab was well tolerated. The majority of adverse events were mild and moderate. The most frequent treatment-related adverse events were lymphopenia, increased alanine aminotransferase, hypercholesterolemia. Adverse events of grade 3–4 were observed in 2%.

Conclusion. Netakimab demonstrated sustained efficacy in key psoriatic arthritis domains at week 54 with a favorable longterm safety profile.

netakimab, psoriatic arthritis, interleukin-17 inhibitors

1. Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:1665. doi: 10.12688/f1000research.19144.1

2. Van der Heijde D, Gladman DD, Kavanaugh A, Mease PJ. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Res Ther. 2020;22(1):18. doi: 10.1186/s13075-020-2103-8

3. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):2095–2096. doi: 10.1056/NEJMc1704342

4. Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: The clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2). doi: 10.3390/ijms19020530

5. Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379−390. doi: 10.1007/s12016-018-8702-3

6. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950−957. doi: 10.1038/ni1497

7. Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66(5):1272−1281. doi: 10.1002/art.38376

8. Mazurov VI, Erdes SF, Gaydukova IZ, Dubinina TV, Pristrom AM, Kunder EV, et al. Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(4):39−49 (In Russ.). doi: 10.14412/1996-7012-2020-4-39-49

9. Kubanov AA, Bakulev AL, Samtsov AV, Khairutdinov VR, Sokolovskiy EV, Kokhan MM, et al. Netakimab – new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-to-severe plaque psoriasis. Vestnik Dermatologii i Venerologii = Dermatology and Venereology Bulletin. 2019;95(2):15−28 (In Russ.). doi: 10.25208/0042-4609-2019-95-2-15-28

10. Korotaeva TV, Mazurov VI, Lila AM, Gaydukova IZ, Bakulev AL, Samtsov AV, et al. Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2020;58(5):480-488 (In Russ.). doi: 10.47360/1995-4484-2020-480-488

11. Korotaeva TV, Samtsov AV, Khairutdinov VR, Bakulev AL, Mladov VV, Eremeeva AV, et al. Netakimab in anti-TNF-naïve patients with psoriatic arthritis: subanalysis of PATERA clinical trial. Consilium Medicum. 2020;22(7):14−19 (In Russ.). doi: 10.26442/20751753.2020-7.200319

12. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665−2673. doi: 10.1002/art.21972

13. Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018;9(1):5-21. doi: 10.1177/2040622317738910

14. Mease P, Roussou E, Burmester GR, Goupille P, Gottlieb A, Moriarty SR., et al. Safety of ixekizumab in patients with psoriatic arthritis: Results from a pooled analysis of three clinical trials. Arthritis Care Res (Hoboken). 2019;71(3):367−378. doi: 10.1002/acr.23738

15. Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317−2327. doi: 10.1016/S0140-6736(17)31429-0

16. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018;4(2):e000723. doi: 10.1136/rmdopen-2018-000723

17. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137−1146. doi: 10.1016/S0140-6736(15)61134-5

18. Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79−87. doi: 10.1136/annrheumdis-2016-209709

19. Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, et al. Shortand long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432−440. e17. doi: 10.1016/j.jaad.2016.09.026